Citius Oncology, Inc. (CTOR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 28, 2025, by Citius Oncology, Inc., a Delaware corporation and emerging growth company. The filing details a material definitive agreement entered into on March 28, 2025, regarding the company's exclusive license for the product LYMPHIR (denileukin diftitox) from Eisai Co., Ltd. Citius Oncology became a stand-alone public company in August 2024, assuming rights and obligations previously held by its former parent, Citius Pharmaceuticals, Inc.
Key Financial Metrics and Obligations
The filing outlines specific financial obligations related to the LYMPHIR license agreement:
- Total Obligation to Eisai: Approximately $8.23 million in aggregate development and inventory costs, plus a $5.9 million milestone payment triggered by FDA approval in August 2024.
- Accrued Liabilities (as of Dec 31, 2024): $6.05 million in inventory costs and $185,317.70 in accounts receivable development costs were accrued.
- Upcoming Expense Recognition: Approximately $2.0 million of the total obligation is scheduled to be recognized in the financial statements for the period ended March 31, 2025.
- Liquidity Impact: The filing does not provide current cash balance, total revenue, or profit metrics. It focuses solely on the restructuring of specific payables.
Material Changes and Agreement Terms
On March 28, 2025, Citius Oncology and Eisai executed a letter agreement amending the original License Agreement to establish a new payment schedule for the outstanding obligations. This change addresses the failure to pay the milestone and other costs by their original due dates.
- Payment Schedule:
- First Payment: $2,535,317.77 due on or before July 15, 2025.
- Subsequent Payments: $2,350,000 due on the 15th of each of the next four months (August through November 2025).
- Final Payment: $2,197,892.07 due on or before December 15, 2025.
- Interest: Interest accrues on each obligation at a rate of 2% per annum from the original due date until the date of actual payment.
- Release of Claims: Both parties released each other from claims related to the prior failure to pay, except for claims arising from a breach of this new letter agreement.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, revenue projections, or general management commentary regarding the company's overall business outlook. The primary risk disclosed is the company's liquidity position relative to the scheduled payments totaling over $11 million (principal plus interest) due between July and December 2025. The agreement confirms that all other terms of the License Agreement remain in full force and effect.
Key Facts for Investor Verification
- Verify the company's current cash and cash equivalents to assess ability to meet the $2.53 million payment due July 15, 2025, and subsequent monthly payments.
- Confirm the exact interest accrual calculation based on the original due dates of the milestone and development costs.
- Review the Q1 2025 financial statements (when filed) to confirm the recognition of the remaining $1.99 million in expenses.
- Monitor for any future amendments to the payment schedule if liquidity constraints arise.